In 2020, with the positive results obtained from the IMbrave150 study (NCT03434379) (17), atezolizumab (PD-L1 inhibitors) combined with bevacizumab (anti-VEGF agent) has been approved as the preferred therapy for advanced HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.